{"id":"W3015552022","doi":"10.1016/j.annonc.2020.03.299","title":"JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Research and Development; Shionogi; Sanofi K.K.; Pharmacyclics; Sierra Oncology; Eli Lilly Japan; Abbott Japan; Novartis Pharma; AstraZeneca; Genentech; Celgene; Yakult Honsha; Otsuka Pharmaceutical; Daiichi Sankyo Europe; European Society for Medical Oncology; Pfizer Japan; Meiji Seika Pharma; Daiichi-Sankyo; Seagen; Revolution Medicines; Japan Society of Clinical Oncology; Jiangsu Hengrui Medicine; BeiGene; Astellas Pharma; Eisai; FibroGen; Japan Blood Products Organization; Eli Lilly and Company; EA Pharma Co., Ltd.; Les Laboratories Pierre Fabre; Ipsen; Array BioPharma; MSD K.K.; F. Hoffmann-La Roche; Boehringer Ingelheim Japan; Halozyme; Servier; Gilead Sciences; GlaxoSmithKline; Foundation Medicine; Kowa Company; Sanofi; Medtronic Japan; Amgen; Chugai Pharmaceutical; Symphogen; Pfizer; Biogen","keywords":"Medicine; Pembrolizumab; Microsatellite instability; Oncology; Clinical trial; Companion diagnostic; Internal medicine; Clinical Oncology; Cancer; Trk receptor; Immunotherapy; Receptor; Neurotrophin; Gene; Microsatellite","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01915164,0.001539191,0.002793613,0.005194777,0.001770493,0.003473847,0.004390406,0.007995643,0.008092838],"category_scores_gemma":[0.04487422,0.0007372037,0.005633283,0.003082457,0.001180113,0.001793767,0.003923189,0.006819254,0.00673897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003760311,"about_ca_system_score_gemma":0.01506561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01159607,"about_ca_topic_score_gemma":0.01490102,"domain_scores_codex":[0.9875178,0.004815777,0.003519931,0.0004651068,0.002760052,0.0009212373],"domain_scores_gemma":[0.9675808,0.008964832,0.005024201,0.0009818481,0.01498996,0.00245836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004462915,0.0001837522,0.005220692,0.00962501,0.0009401226,0.0003436855,0.0002721762,0.002097919,0.001178546,0.004522058,0.6549312,0.3202384],"study_design_scores_gemma":[0.0005221271,0.0001768308,0.008413567,0.03000452,0.001512624,0.0008889181,0.0004467178,0.001810984,0.001026827,0.008827158,0.9462202,0.0001495238],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.006838732,0.2561522,0.04445549,0.4951282,0.03978763,0.004616838,0.01276682,0.001548582,0.1387054],"genre_scores_gemma":[0.08973847,0.2639354,0.2377042,0.261123,0.02942506,0.0112934,0.05139709,0.001606397,0.053777],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01915164,"threshold_uncertainty_score":0.1012848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1042766919116311,"score_gpt":0.3936264719376828,"score_spread":0.2893497800260517,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}